RANDOX URINE CONTROLS

K043266 · Randox Laboratories, Ltd. · JJW · Feb 15, 2005 · Clinical Chemistry

Device Facts

Record IDK043266
Device NameRANDOX URINE CONTROLS
ApplicantRandox Laboratories, Ltd.
Product CodeJJW · Clinical Chemistry
Decision DateFeb 15, 2005
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 862.1660
Device ClassClass 1

Intended Use

The Randox Laboratories Ltd. Urine Controls are based on lyophilized human and have been developed for the control of both accuracy and precision in clinical chemistry applications, particularly urine analysis. These control materials are available at two constituent concentrations. The Randox Assayed and Unassayed Urine Controls should only be used by suitably qualified personnel under appropriate laboratory conditions.

Device Story

Randox Urine Controls consist of lyophilized human urine; provided at two constituent concentrations. Used as quality control material to verify accuracy and precision of clinical chemistry urine analysis assays. Operated by qualified laboratory personnel in clinical laboratory settings. Provides a reference standard for comparison against patient sample results to ensure analytical performance of clinical chemistry systems.

Clinical Evidence

No clinical data; bench testing only.

Technological Characteristics

Lyophilized human urine/serum/bovine hemoglobin matrix. Reconstituted with distilled water. Stability: 5 days at 4°C, 14 days at -20°C. Analyte concentrations spiked to meet target ranges. Class I (reserved) device.

Indications for Use

Indicated for use as quality control material for monitoring accuracy and precision in clinical chemistry urine analysis. Intended for use by qualified laboratory personnel.

Regulatory Classification

Identification

A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's emblem, which is a stylized depiction of an eagle with three lines extending from its head, representing the department's mission to protect the health of all Americans and provide essential human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the emblem in a circular fashion. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 FEB 1 5 2005 Dr. Pauline Armstrong Regulatory Affairs Randox Laboratories Ltd. 55 Diamond Road Crumlin, Co. Antrim United Kingdom BT29 4QY k043266 Re: Trade/Device Name: Randox Urine Controls Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJW Dated: January 18, 2005 Received: January 21, 2005 Dear Dr. Armstrong: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {1}------------------------------------------------ ## Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html Sincerely yours, Jean M. Cooper, MS, DUM Jean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use 510(k) Number (if known) K043266 Assayed and Unassayed Urine Controls Device Name: Indications For Use: The Randox Laboratories Ltd. Urine Controls are based on lyophilised human urine and have been developed for the control of both accuracy and precision in clinical chemistry applications particularly urine analysis. These control materials are available at two constituent concentrations. The Randox Assayed and Unassayed Urine Controls should only be used by suitably qualified laboratory personnel under appropriate laboratory conditions. Prescription Use (Part 21 CFR 801 Subpart D) V AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) ## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Division Sign-Off acting Office of in Vitto Diac Device Evaluation an 510(k) KOH3266
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...